Sugi Predict

Sugi Predict / Targets / MOGAT2

MOGAT2

2-acylglycerol O-acyltransferase 2 · Q3SYC2 · MOGAT2 on Sugi Atlas →

6,527 patent compounds predicted against MOGAT2, 3,010 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4563873 SCHEMBL4563873 0.54 19/20
SCHEMBL3177067 SCHEMBL3177067 0.41 11/20
SCHEMBL3992124 SCHEMBL3992124 0.51 10/20
SCHEMBL4898502 SCHEMBL4898502 0.48 10/20
SCHEMBL5361693 SCHEMBL5361693 0.56 9/20
SCHEMBL5363269 SCHEMBL5363269 0.55 9/20
SCHEMBL5362681 SCHEMBL5362681 0.50 9/20
SCHEMBL5366306 SCHEMBL5366306 0.50 9/20
SCHEMBL3171902 SCHEMBL3171902 0.41 9/20
SCHEMBL5358930 SCHEMBL5358930 0.57 8/20
SCHEMBL5357697 SCHEMBL5357697 0.56 8/20
SCHEMBL5365967 SCHEMBL5365967 0.56 8/20
SCHEMBL5363201 SCHEMBL5363201 0.55 8/20
SCHEMBL5368785 SCHEMBL5368785 0.55 8/20
SCHEMBL5358224 SCHEMBL5358224 0.54 8/20
SCHEMBL5367621 SCHEMBL5367621 0.52 8/20
SCHEMBL4434244 SCHEMBL4434244 0.43 8/20
SCHEMBL3188313 SCHEMBL3188313 0.41 8/20
SCHEMBL1770239 SCHEMBL1770239 0.35 8/20
SCHEMBL5361553 SCHEMBL5361553 0.57 7/20

Clinical trials — most relevant to MOGAT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Omega 3 and Ischemic Stroke; Fish Oil as an Option PHASE4UNKNOWN
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders nanCOMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Psychological and Biological Markers of Refractory Migraine nanUNKNOWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
CT Body Composition Enhances Survival Risk Stratification nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Choline to Improve Malnutrition and Enhance Cognition nanRECRUITING
Epidemiology of Atherosclerosis nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
RCDP Natural History Study nanUNKNOWN
Fat-induced Release of GLP-1 in Humans nanCOMPLETED
Genetic Determinants:Low HDL, High Triglycerides, Obesity nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MOGAT2 binder may also engage these)

ProteinNameSimilarity
Q80W94 — 0.998 Q80W94 →
Q70VZ7 — 0.996 Q70VZ7 →
Q3KPP4 — 0.991 Q3KPP4 →
Q2KHS5 — 0.988 Q2KHS5 →
Q28C88 — 0.987 Q28C88 →
Q96PD6 — 0.985 Q96PD6 →
Q70VZ8 — 0.985 Q70VZ8 →
Q5M8H5 — 0.984 Q5M8H5 →
Q5M7F4 — 0.980 Q5M7F4 →
DGAT2 Diacylglycerol O-acyltransferase 2 0.974 landscape →
Q6PAZ3 — 0.973 Q6PAZ3 →
Q5FVP8 — 0.973 Q5FVP8 →
Q6P342 — 0.972 Q6P342 →
Q9DCV3 — 0.968 Q9DCV3 →
Q91ZV4 — 0.967 Q91ZV4 →
Q4V9F0 — 0.965 Q4V9F0 →
Q8K3K7 — 0.953 Q8K3K7 →
Q58HT5 — 0.948 Q58HT5 →
A6QP72 — 0.946 A6QP72 →
Q6ZPD8 — 0.946 Q6ZPD8 →
Q9ASU1 — 0.945 Q9ASU1 →
Q4R3Y4 — 0.943 Q4R3Y4 →
A2ADU8 — 0.943 A2ADU8 →
P79381 — 0.941 P79381 →
A0A0M4FCN7 — 0.941 A0A0M4FCN7 →
K7K424 — 0.941 K7K424 →
AGPAT2 1-acyl-sn-glycerol-3-phosphate acyltransferase beta 0.940 landscape →
Q9D850 — 0.940 Q9D850 →
Q6P1M0 — 0.940 Q6P1M0 →
O54753 — 0.940 O54753 →